<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
SCHEDULE 13G/A
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) AND (c) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)
(Amendment No. 1)*
TRIANGLE PHARMACEUTICALS, INC.
-------------------------------------------------------------------------------
(NAME OF ISSUER)
COMMON STOCK
-------------------------------------------------------------------------------
(TITLE OF CLASS OF SECURITIES)
89589H 10 4
-------------------------------------------------------------------------------
(CUSIP NUMBER)
_________________
- -------------------
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
(CONTINUED ON FOLLOWING PAGE(S))
(PAGE 1 of 5 PAGES)
<PAGE>
- ------------------------------- -----------------------
CUSIP NO. 89589H 10 4 13G Page 2 of 5 Pages
- ------------------------------- -----------------------
- -------------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS.
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
DAVID W. BARRY, M.D.
- -------------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / / (b) / /
- -------------------------------------------------------------------------------
(3) SEC USE ONLY
- -------------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- -------------------------------------------------------------------------------
NUMBER OF SHARES (5) SOLE VOTING POWER
BENEFICIALLY 1,273,881(+) shares of Common Stock
OWNED BY --------------------------------------------------
EACH REPORTING (6) SHARED VOTING POWER
PERSON WITH 30,000(++)
--------------------------------------------------
(7) SOLE DISPOSITIVE POWER
1,273,881(+) shares of Common Stock
--------------------------------------------------
(8) SHARED DISPOSITIVE POWER
30,000(++)
- -------------------------------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,303,881(+)(++) shares of Common Stock
- -------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
/ /
- -------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.5% as of December 31, 1997
- -------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON*
IN
- -------------------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
+ Includes 25,381 shares of Common Stock issuable upon the exercise of
options that are exercisable within 60 days of December 31, 1997.
++ Includes 30,000 shares of Common Stock held by the Barry Charitable
Foundation, Inc., a charitable North Carolina corporation of which
Dr. Barry serves as President.
<PAGE>
Page 3 of 5 Pages
ITEM 1(a) NAME OF ISSUER:
Triangle Pharmaceuticals, Inc.
ITEM 1(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
4 University Place
4611 University Drive
Durham, NC 27707
ITEM 2(a) NAME OF PERSON FILING:
David W. Barry, M.D.
ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Triangle Pharmaceuticals, Inc.
4 University Place
4611 University Drive
Durham, NC 27707
ITEM 2(c) CITIZENSHIP:
United States
ITEM 2(d) TITLE OF CLASS OF SECURITIES:
Common Stock
ITEM 2(e) CUSIP NUMBER:
89589H 10 4
<PAGE>
Page 4 of 5 Pages
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR
13d-2(b), CHECK WHETHER THE PERSON FILING IS A:
Not Applicable
ITEM 4. OWNERSHIP.
(a) Amount Beneficially Owned: 1,303,881(+)(++) shares of Common
Stock
(b) Percent of Class: 6.5%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
1,273,881(+)
(ii) shared power to vote or to direct the vote:
30,000(++)
(iii) sole power to dispose or to direct the disposition
of: 1,273,881(+)
(iv) shared power to dispose or to direct the
disposition of: 30,000(++)
+ Includes 25,381 shares of Common Stock issuable upon the exercise of
options that are exercisable within 60 days of December 31, 1997.
++ Includes 30,000 shares of Common Stock held by the Barry Charitable
Foundation, Inc., a charitable North Carolina corporation of which
Dr. Barry serves as President.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not Applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY.
Not Applicable
<PAGE>
Page 5 of 5 Pages
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not Applicable
ITEM 10. CERTIFICATION.
Not Applicable.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: February 11, 1998
Signature: /s/ David W. Barry, M.D.
--------------------------------
Name/Title: David W. Barry, M.D.
